Current Status and Progress of Breast Adenoid Cystic Carcinoma
Dongwei Zhang1, 2
1 The Second Hospital of Harbin Medical University, Harbin, 150081, China
2 Heilongjiang Academy of Medical Sciences, Harbin, 150081, China
Cancer Genetics and Epigenetics, 2017, Vol. 5, No. 2 doi: 10.5376/cge.2017.05.0002
Received: 31 Oct., 2017 Accepted: 06 Nov., 2017 Published: 20 Nov., 2017
© 2017 BioPublisher Publishing Platform
This is an open access article published under the terms of the Creative Commons Attribution License
, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Preferred citation for this article:
Zhai Z.W., You S.R., Zhao B.Z., Zhang J.Y., and Zhang D.W., 2017, Current status and progress of breast adenoid cystic carcinoma, Cancer Genetics and Epigenetics, 5(2): 6-10 (doi: 10.5376/cge.2017.05.0002)
Adenoid cystic carcinoma (ACC) of the breast is a rare subtype of breast cancer. Despite its triple-negative status, this tumor has a very good prognosis. Breast-conserving treatment including postoperative radiotherapy seems to be equivalent to mastectomy alone with respect to survival. Routine axillary lymph node staging is not recommended since lymph node metastases are extremely rare. The value of adjuvant systemic therapies is not established. Late relapses can occur, so long-term follow-up is mandatory for these patients.
Adenoid cystic carcinoma; Breast cancer; Radiotherapy; Surgery; Therapy
Cancer Genetics and Epigenetics
• Volume 5